Torrent Pharmaceuticals
3,603.80
+83.90(+2.38%)
Market Cap₹1,19,129.40 Cr
PE Ratio62.12
IndustryHealthcare
Company Performance:
1D+2.38%
1M+11.69%
6M+7.97%
1Y+16.81%
5Y+213.46%
View Company Insightsright
More news about Torrent Pharmaceuticals
04Jul 25
Torrent Pharma Expands Stake in JB Chemicals with ₹620 Crore Deal
Torrent Pharmaceuticals has signed an agreement to acquire an additional 2.41% stake in JB Chemicals for ₹620 crore, at ₹1,600 per share. This follows a recent acquisition of a 46.39% controlling stake for ₹11,917 crore. The move is part of Torrent's strategy to fully integrate JB Chemicals, with plans for a merger post-acquisition. This acquisition aims to expand Torrent's market presence, create operational synergies, and enhance its competitive position in the pharmaceutical industry.
01Jul 25
Torrent Pharma's Target Price Upgraded by BofA Securities on JB Pharma Acquisition Synergies
BofA Securities has increased Torrent Pharmaceuticals' target price to Rs 3,500.00 from Rs 3,300.00 after its acquisition of JB Pharma. The upgrade is based on expected margin synergies of 250-300 basis points by FY27-28. The merger is anticipated to positively impact earnings per share from the first year post-completion, strengthening Torrent's position in the domestic pharmaceutical market.
30Jun 25
Torrent Pharmaceuticals Set to Acquire JB Chemicals in ₹19,500 Crore Deal
Torrent Pharmaceuticals plans to acquire JB Chemicals and Pharmaceuticals in a ₹19,500 crore deal over 15-18 months. The acquisition will be executed in stages: purchasing a 46.39% stake from JB Chemicals' promoter, acquiring 2.80% from employees, and making a mandatory open offer for up to 26% from public shareholders. Post-acquisition, JB Chemicals is expected to merge into Torrent Pharmaceuticals, potentially strengthening Torrent's market position.
21May 25
Torrent Pharma Q4 Results Meet Expectations, Analysts Remain Optimistic
Torrent Pharmaceuticals' Q4 results met market expectations with improved profitability. The company reported an adjusted EBITDA margin of 33.20%, up 60 basis points quarter-on-quarter. Strong growth was seen in both Indian and US markets. Citi maintained a positive outlook with a price target of ₹4,000.00. Torrent plans to add 1,200 new sales personnel over FY2024-2026.
20May 25
Torrent Pharmaceuticals: Q4 Profit Up 11%, Plans Rs 5,000-Crore Fundraise
Torrent Pharmaceuticals announced Q4 results with an 11% increase in net profit to ₹498 crore and a 7.8% rise in revenue to ₹2,959 crore. The company declared a final dividend of ₹6 per share and is seeking approval for a ₹5,000 crore share issuance. The board recommended Aman Mehta for the role of Managing Director.
13May 25
Torrent Pharma to Explore Fundraising Options in Upcoming Board Meeting
Torrent Pharmaceuticals has announced a board meeting scheduled for May 20 to discuss and consider potential fundraising options. This development suggests the company may be exploring ways to secure additional capital, which could be used for expansion, R&D, debt reduction, or acquisitions. The outcome of this meeting will be closely watched by investors and market analysts as it could provide insights into the company's financial strategy and future growth plans.
27Mar 25
Torrent Pharmaceuticals Raises ₹200 Crore Through Commercial Paper Issuance
Torrent Pharmaceuticals Limited has successfully raised ₹200 crore through the issuance of commercial papers with a 93-day tenure. The papers, set to mature on June 27, 2025, carry a coupon rate of 7.13% per annum and are proposed to be listed on the National Stock Exchange of India. This unsecured short-term debt instrument issuance demonstrates the company's strong market position and ability to access cost-effective funding for operational needs.
26Mar 25
Torrent Pharmaceuticals Raises ₹200 Crore Through Commercial Paper Issue
Torrent Pharmaceuticals has issued commercial papers worth ₹200 crore with a 93-day tenure at 7.13% per annum. The papers, set to mature on June 27, 2025, are unsecured and proposed for listing on NSE. Simultaneously, the company announced full redemption of a previous ₹200 crore commercial paper issuance, demonstrating active short-term debt management.
25Mar 25
Torrent Pharmaceuticals Raises ₹300 Crore Through Commercial Paper Issue
Torrent Pharmaceuticals has issued commercial papers worth ₹300 crore with a 90-day tenure. The papers, allotted on March 25, 2025, will mature on June 23, 2025, carrying a 7.13% per annum coupon rate. They are unsecured and proposed to be listed on the National Stock Exchange of India. This move demonstrates the company's strong financial position and efficient access to capital markets, potentially aimed at optimizing cash management or funding short-term operational needs.
10Mar 25
Torrent Pharma to Launch Affordable Diabetes Medication, Boosting Treatment Accessibility
Torrent Pharmaceuticals Ltd is planning to introduce an affordable version of empagliflozin, a vital medication for type 2 diabetes. This move is part of a broader initiative by Indian pharmaceutical companies to improve access to essential medications. The launch of low-cost empagliflozin is expected to enhance accessibility for a larger diabetic population, potentially reshape the diabetes care market in India, and increase competition while reducing overall treatment costs.
28Feb 25
Torrent Pharma Set for $43 Million Inflow as MSCI India Index Weightage Increases
Torrent Pharmaceuticals' weightage in the MSCI India Standard Index is set to increase, potentially triggering a $43 million (Rs 3.76 billion) inflow into the stock. This adjustment, effective today at 3 PM, is expected to boost liquidity and attract more passive funds and index-tracking investors. Separately, Pranav Mehta, Executive Director (Strategic Planning), has resigned effective February 26, 2025, to pursue new career opportunities.
Torrent Pharmaceuticals
3,603.80
+83.90
(+2.38%)
1 Year Returns:+16.81%
Industry Peers
Sun Pharmaceutical
1,699.00
(+0.41%)
Divis Laboratories
6,616.50
(-0.03%)
Cipla
1,532.50
(+3.00%)
Torrent Pharmaceuticals
3,603.80
(+2.38%)
Mankind Pharma
2,603.40
(+0.54%)
Dr Reddys Laboratories
1,277.90
(+0.98%)
Zydus Life Science
976.40
(+0.53%)
Lupin
1,951.00
(+0.49%)
Abbott
33,780.00
(-2.31%)
Aurobindo Pharma
1,122.80
(+0.78%)